Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Regulus Therapeutics stock

Own Regulus Therapeutics stock in just a few minutes.

Regulus Therapeutics Inc is a biotechnology business based in the US. Regulus Therapeutics shares (RGLS) are listed on the NASDAQ and all prices are listed in US Dollars. Regulus Therapeutics employs 24 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Regulus Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – RGLS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Regulus Therapeutics share price

Use our graph to track the performance of RGLS stocks over time.

Regulus Therapeutics shares at a glance

Information last updated 2021-04-23.
52-week range$0.42 - $1.97
50-day moving average $1.49
200-day moving average $1.14
Wall St. target price$1.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.43

Buy Regulus Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Regulus Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Regulus Therapeutics financials

Revenue TTM $10 million
Gross profit TTM $-5,341,000
Return on assets TTM -22.21%
Return on equity TTM -68.33%
Profit margin -157.21%
Book value $0.39
Market capitalisation $96.5 million

TTM: trailing 12 months

Shorting Regulus Therapeutics shares

There are currently 6.7 million Regulus Therapeutics shares held short by investors – that's known as Regulus Therapeutics's "short interest". This figure is 31.4% up from 5.1 million last month.

There are a few different ways that this level of interest in shorting Regulus Therapeutics shares can be evaluated.

Regulus Therapeutics's "short interest ratio" (SIR)

Regulus Therapeutics's "short interest ratio" (SIR) is the quantity of Regulus Therapeutics shares currently shorted divided by the average quantity of Regulus Therapeutics shares traded daily (recently around 5.3 million). Regulus Therapeutics's SIR currently stands at 1.26. In other words for every 100,000 Regulus Therapeutics shares traded daily on the market, roughly 1260 shares are currently held short.

However Regulus Therapeutics's short interest can also be evaluated against the total number of Regulus Therapeutics shares, or, against the total number of tradable Regulus Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Regulus Therapeutics's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Regulus Therapeutics shares in existence, roughly 90 shares are currently held short) or 0.1145% of the tradable shares (for every 100,000 tradable Regulus Therapeutics shares, roughly 115 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Regulus Therapeutics.

Find out more about how you can short Regulus Therapeutics stock.

Regulus Therapeutics share dividends

We're not expecting Regulus Therapeutics to pay a dividend over the next 12 months.

Have Regulus Therapeutics's shares ever split?

Regulus Therapeutics's shares were split on a 1:12 basis on 3 October 2018. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Regulus Therapeutics shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Regulus Therapeutics shares which in turn could have impacted Regulus Therapeutics's share price.

Regulus Therapeutics share price volatility

Over the last 12 months, Regulus Therapeutics's shares have ranged in value from as little as $0.4222 up to $1.97. A popular way to gauge a stock's volatility is its "beta".

RGLS.US volatility(beta: 2.39)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Regulus Therapeutics's is 2.3878. This would suggest that Regulus Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Regulus Therapeutics overview

Regulus Therapeutics Inc. , a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase 1 development for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products, which include RGLS5579 glioblastoma multiforme program; and Hepatitis B virus, non-alcoholic steatohepatitis, and cell therapies programs. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site